The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer
Open accessAbstract
Purpose: Adjuvant! ( www.adjuvantonline.com ) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated. Methods: Using the British Columbia Breast Cancer Outcomes Unit (BCOU) database, demographic, pathologic, staging, and treatment data on 4,083 women diagnosed between 1989 and 1993 in British Columbia with T1-2, N0-1, M0 breast cancer were abstracted and entered into Adjuvant! to calculate predicted 10-year overall survival (OS), breast cancer–specific survival (BCSS), and event-free survival (EFS) for each patient. Individual BCOU observed outcomes at 10 years were independently determined. Predicted and observed outcomes were compared. Results: Across all 4,083 patients, 10-year predicted and observed outcomes were within 1% for OS, BCSS, and EFS (all P > .05). Predicted and observed outcomes were within 2% for most demographic, pathologic, and treatment-defined subgroups. Adjuvant! overestimated OS, BCSS, and EFS in women younger than age 35 years (predicted − observed = 8.6%, 9.6%, and 13.6%, respectively; all P < .001) or with lymphatic or vascular invasion (LVI; predicted − observed = 3.6%, 3.8%, and 4.2%, respectively; all P < .05); these two prognostic factors were not automatically incorporated within the Adjuvant! algorithm. After adjusting for the distribution of LVI, using the prognostic factor impact calculator in Adjuvant!, 10-year predicted and observed outcomes were no longer significantly different. Conclusion: Adjuvant! performed reliably. Patients younger than age 35 or with known additional adverse prognostic factors such as LVI require adjustment of risks to derive reliable predictions of prognosis without adjuvant systemic therapy and the absolute benefits of adjuvant systemic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Ravdin, P. M., Siminoff, L. A., Davis, G. J., Mercer, M. B., Hewlett, J., Gerson, N., & Parker, H. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.980 · Cited by 996
Self-citationNixon, A. J., Neuberg, D., Hayes, D. F., Gelman, R., Connolly, J. L., Schnitt, S., Abner, A., Recht, A., Vicini, F., & Harris, J. R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.888 · Cited by 579
Fourquet, A., Campana, F., Zafrani, B., Mosseri, V., Vielh, P., Durand, J.-C., & Vilcoq, J. R. (1989) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(89)90057-6 · Cited by 509
Gasparini, G., Weidner, N., Bevilacqua, P., Maluta, S., Dalla Palma, P., Caffo, O., Barbareschi, M., Boracchi, P., Marubini, E., & Pozza, F. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.454 · Cited by 464
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Aebi, S., Gelber, S., Castiglione-Gertsch, M., Gelber, R., Collins, J., Thürlimann, B., Rudenstam, C., Lindtner, J., Crivellari, D., Cortes-Funes, H., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02292-3 · Cited by 287
Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.
Ravdin, P. M., Siminoff, I. A., & Harvey, J. A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.515 · Cited by 262
Self-citationWhelan, T., Sawka, C., Levine, M., Gafni, A., Reyno, L., Willan, A., Julian, J., Dent, S., Abu-Zahra, H., Chouinard, E., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.581 · Cited by 226
Doctor-patient communication about breast cancer adjuvant therapy.
Siminoff, L. A., Fetting, J. H., & Abeloff, M. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1192 · Cited by 217
Weir, L., Speers, C. H., Dyachkova, Y., & Olivotto, I. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.112 · Cited by 149
Self-citationUnderstanding the Utility of Adjuvant Systemic Therapy for Primary Breast Cancer
Loprinzi, C. L., & Thomé, S. D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.972 · Cited by 95
Compliance with practice guidelines for node-negative breast cancer.
Olivotto, A., Coldman, A. J., Hislop, T. G., Trevisan, C. H., Kula, J., Goel, V., & Sawka, C. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.216 · Cited by 80
Self-citationComments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer
Senn, H.-J., Thurlimann, B. J. K., Goldhirsch, A., Wood, W. C., Gelber, R. D., & Coates, A. S. (2003) · The Breast · doi:10.1016/j.breast.2003.09.007 · Cited by 42
Cited by
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249
Self-citation70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., Brain, E., Causeret, S., DeLorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,994
Self-citation
Metadata
- Authors
- Olivotto, I. A., Bajdik, C. D., Ravdin, P. M., Speers, C. H., Coldman, A. J., Norris, B. D., Davis, G. J., Chia, S. K., & Gelmon, K. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-04-20
- Volume
- 23
- Issue
- 12
- Pages
- 2716-2725
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097977223
- Cited by
- 567
- References
- 15
- FWCI
- 15.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.